EIR from USFDA, for Shilpa Medicare Ltd. Unit VI, Bengaluru.

Shilpa Medicare Limited, Unit VI, Dabaspet, Bengaluru, Karnataka, India has received EIR with VAI (Voluntary Action Indicated) classification, from USFDA, for the GMP inspection which was conducted from October 24 - 30, 2024.

This facility is capable of manufacturing, packaging, testing, storage and distribution of two types of complex dosage forms - Oral Dissolving Films and Transdermal Systems.

The Unit is already approved by EMA, Europe; MHRA, UK; SFDA, Saudi and TGA, Australia.

This Unit is currently supplying Oral Film products to US and other markets. Transdermal products have been filed in the European market.

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 894.40 as compared to the previous close of Rs. 905.45. The total number of shares traded during the day was 2093 in over 131 trades.

The stock hit an intraday high of Rs. 914.85 and intraday low of 891.25. The net turnover during the day was Rs. 1887966.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 Pharmaceuticals EIR VAIStatus USFDA GMPInspection Unit6 Dabaspet